Document:

Exhibit10.1

EXECUTION COPY

FIRST AMENDMENT TO CREDIT AGREEMENT
THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of July 27, 2015, is by and among ADOBE SYSTEMS INCORPORATED, a Delaware corporation (the “Company”), the Lenders party hereto, and BANK OF AMERICA, N.A., as Administrative Agent and Swing Line Lender (in such capacity, the “Administrative Agent”).  Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Credit Agreement.
W I T N E S S E T H
WHEREAS, the Company, certain Subsidiaries of the Company from time to time party thereto, certain banks and financial institutions from time to time party thereto (the “Lenders”) and the Administrative Agent are parties to that certain Credit Agreement, dated as of March 2, 2012 (as amended, amended and restated, extended, supplemented or otherwise modified from time to time, the “Credit Agreement”);
WHEREAS, the Company has requested that the Lenders amend certain provisions of the Credit Agreement; and
WHEREAS, the Lenders are willing to make such amendments to the Credit Agreement, in accordance with and subject to the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the agreements hereinafter set forth, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:
ARTICLE I 
AMENDMENTS TO CREDIT AGREEMENT
1.1    New Definitions.  The following definitions are hereby added to Section 1.01 of the Credit Agreement in the appropriate alphabetical order:
“Designated Jurisdiction” means any country or territory to the extent that such country or territory itself is, or whose government is, the subject of any Sanction.
“HMT” has the meaning specified in the definition of “Sanctions(s)”.
“LIBOR” has the meaning specified in clause (a) of the definition of “Eurocurrency Rate”.
“OFAC” means the Office of Foreign Assets Control of the United States Department of the Treasury.
“Sanction(s)” means any sanction administered or enforced by the United States Government (including without limitation, OFAC), the United Nations Security Council, the European Union, Her Majesty’s Treasury (“HMT”)  or other relevant sanctions authority.
1.2    Amendments to Certain Definitions.  The following definitions set forth in Section 1.01 of the Credit Agreement are hereby amended as follows:

1

(a)    The definition of “Base Rate” is hereby amended by inserting the following phrase at the end of the first sentence of such definition:
; and if the Base Rate shall be less than zero, such rate shall be deemed zero for purposes of this Agreement.
(b)    The definition of “Committed Loan Notice” is hereby amended and restated in its entirety to read as follows:
“Committed Loan Notice” means a notice of (a) a Committed Borrowing, (b) a conversion of Committed Loans from one Type to the other, or (c) a continuation of Eurocurrency Rate Loans, pursuant to Section 2.02(a),  which shall be substantially in the form of Exhibit A or such other form as may be approved by the Administrative Agent (including any form on an electronic platform or electronic transmission system as shall be approved by the Administrative Agent), appropriately completed and signed by a Responsible Officer of the applicable Borrower.
(c)    Clause (a) of the definition of “Eurocurrency Rate” is hereby amended and restated in its entirety to read as follows:
(a)    for any Interest Period with respect to a Eurocurrency Rate Loan, the rate per annum equal to the London Interbank Offered Rate (“LIBOR”) or a comparable or successor rate which rate is approved by the Administrative Agent, as published on the applicable Bloomberg screen page (or such other commercially available source providing such quotations as may be designated by the Administrative Agent from time to time) at approximately 11:00 a.m., London time, two Business Days prior to the commencement of such Interest Period, for deposits in the relevant currency (for delivery on the first day of such Interest Period) with a term equivalent to such Interest Period;
(d)    The definition of “Eurocurrency Rate” is hereby further amended by inserting the following proviso at the end of such definition:
; provided that, notwithstanding any of the foregoing to the contrary, if the Eurocurrency Rate shall be less than zero, such rate shall be deemed zero for purposes of this Agreement. 
(e)    Clause (a) of the definition of “Maturity Date” is hereby amended by inserting the date “July 27, 2020” in place of the date presently set forth in such clause.
(f)    The definition of “Responsible Officer” is hereby amended by inserting the following phrase at the end of the first sentence of such definition:
and, solely for purposes of notices given pursuant to Article 2, any other officer or employee of the applicable Loan Party so designated by any of the foregoing officers in a notice to the Administrative Agent or any other officer or employee of the applicable Loan Party designated in or pursuant to an agreement between the applicable Loan Party and the Administrative Agent. 

2

(g)    The definition of “Swing Line Loan Notice” is hereby amended by inserting the following phrase at the end of such definition:
or such other form as approved by the Administrative Agent (including any form on an electronic platform or electronic transmission system as shall be approve by the Administrative Agent), appropriately completed and signed by a Responsible Officer of the Company.
1.3    New Sections.  The following Sections are hereby added to the Credit Agreement in the appropriate numerical order:
(a)    The following new Sections are added to the end of Article 5:
Section 5.20.  Sanctions.  No Loan Party, nor any of Subsidiary of any Loan Party, nor, to the knowledge of any such Person, any director, officer, employee, agent or affiliate thereof, is the subject of any Sanctions, nor is any Loan Party, any such Subsidiary or (to the knowledge of such Person) any such director, officer, employee, agent or affiliate located, organized or resident in a Designated Jurisdiction.
Section 5.21.  Anti-Corruption Laws.  The Company and its Subsidiaries have conducted their businesses in compliance with the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010, and other similar anti-corruption legislation in other jurisdictions and have instituted and maintained policies and procedures designed to promote and achieve compliance with such laws.
(b)    The following new Section 6.14 is added to the end of Article 6:
Section 6.14.  Anti-Corruption Laws.  Conduct its businesses in compliance with the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010, and other similar anti-corruption legislation in other jurisdictions and maintain policies and procedures designed to promote and achieve compliance with such laws. 
(c)    The following new Sections 7.10 and 7.11 are added to the end of Article 7:
Section 7.10.  Sanctions.  No Loan Party shall use the proceeds of any Loan, directly, or to the knowledge of such Loan Party, indirectly, or lend, contribute or otherwise make available such proceeds to any Subsidiary or other Person, to fund any activities of or business with any such Subsidiary or other Person, that, at the time of such funding, is the subject of Sanctions or is otherwise organized or resident in a Designated Jurisdiction.
Section 7.11.  Anti-Corruption Laws.  No Loan Party shall use the proceeds of any Loan, directly, or to the knowledge of such Loan Party, indirectly, for any purpose which would breach the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010, and other similar anti-corruption legislation in other jurisdictions.

3

(d)    The following new Section 10.21 is hereby added to the end Article 10:
Section 10.21.  Electronic Execution of Assignments and Certain Other Documents.  The words “execute,” “execution,” “signed,” “signature,” and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation Assignment and Assumptions, amendments or other modifications, Committed Loan Notices, Swing Line Loan Notices, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act; provided that notwithstanding anything contained herein to the contrary the Administrative Agent is under no obligation to agree to accept electronic signatures in any form or in any format unless expressly agreed to by the Administrative Agent pursuant to procedures approved by it.
1.4    Amendments to Certain Sections.  The following Sections of the Credit Agreement are hereby amended as follows:
(a)    The first sentence of clause (a) of Section 2.02 is hereby amended and restated in its entirety to read as follows:
Each Committed Borrowing, each conversion of Committed Loans from one Type to the other, and each continuation of Eurocurrency Rate Committed Loans shall be made upon the Company’s irrevocable notice to the Administrative Agent, which may be given by (A) telephone or (B) a Committed Loan Notice; provided that any telephonic notice must be confirmed immediately by delivery to the Administrative Agent of a Committed Loan Notice.
(b)    The first sentence of clause (b) of Section 2.05 is hereby amended and restated in its entirety to read as follows:
Each Swing Line Borrowing shall be made upon the Company’s irrevocable notice to the Swing Line Lender and the Administrative Agent, which may be given by (A) telephone or (B) by a Swing line Loan Notice; provided that any telephonic notice must be confirmed promptly by delivery to the Swing line Lender and the Administrative Agent of a Swing Line Loan Notice. 
1.5    Reallocation of Commitments; Amendment to Schedule 2.01.  Each of the parties hereto severally and for itself agrees that on and as of the Amendment Effective Date, each Lender’s Applicable Percentage of the Commitments and portion of the Loans for the purposes of the Credit Agreement and each other Loan Document will be as set forth opposite such Person’s name on Schedule 2.01 to the Credit Agreement, which is amended and restated in its entirety to read as set forth on Exhibit A to this Amendment.  

4

ARTICLE II     
CONDITIONS TO EFFECTIVENESS
2.1    Closing Conditions.  This Amendment shall become effective as of the day and year set forth above (the “Amendment Effective Date”) upon satisfaction of the following conditions (in each case, in form and substance reasonably acceptable to the Administrative Agent) on or prior to July 27, 2015:
(h)    Executed Amendment.  The Administrative Agent shall have received a copy of this Amendment duly executed by the Company, each Lender and the Administrative Agent.
(i)    Default.  On and as of the date of to this Amendment, no Default or Event of Default shall exist.
(j)    Fees and Expenses.  The Administrative Agent shall have received from the Company such fees and expenses that are payable in connection with the consummation of the transactions contemplated hereby and Winstead PC shall have received from the Company payment of all outstanding fees and expenses previously incurred and all fees and expenses incurred in connection with this Amendment.
(k)    Resolutions; Good Standings; etc.  The Administrative Agent shall have received from the Company such documents and certifications as the Administrative Agent may reasonably require to evidence that (i) the resolutions, incumbency certificates and other applicable certificates, in each case, delivered on or about the Closing Date (March 2, 2012) (A) remain in full force and effect on the Amendment Effective Date and (B) no proceedings have been taken to amend, supplement, revoke or repeal any such resolutions or certificates since the date of their adoption; and (ii) the Company is validly existing, in good standing and qualified to engage in business under the laws of Delaware and California.
(l)    Legal Opinion.  The Administrative Agent shall have received an opinion or opinions of counsel for the Company, dated the Amendment Effective Date and addressed to the Administrative Agent and the Lenders which shall be in form and substance reasonably satisfactory to the Administrative Agent and its counsel.
(m)    Miscellaneous.  All other documents and legal matters in connection with the transactions contemplated by this Amendment shall be reasonably satisfactory in form and substance to the Administrative Agent and its counsel.
ARTICLE III     
MISCELLANEOUS
3.1    Amended Terms.  On and after the Amendment Effective Date, all references to the Credit Agreement in each of the Loan Documents shall hereafter mean the Credit Agreement as amended by this Amendment.  Except as specifically amended hereby or otherwise agreed, the Credit Agreement is hereby ratified and confirmed and shall remain in full force and effect according to its terms.
3.2    FATCA.  For purposes of determining withholding Taxes imposed under FATCA, from and after the Amendment Effective Date, the Company and the Administrative Agent shall treat (and the Lenders 

5

hereby authorize the Administrative Agent to treat) the Obligations as not qualifying as a “grandfathered obligation” within the meaning of Treasury Regulation Section 1.1471-2(b)(2)(i).
3.3    Representations and Warranties.  The Company represents and warrants as follows:
(a)    It has taken all necessary action to authorize the execution, delivery and performance of this Amendment.
(b)    This Amendment has been duly executed and delivered by the Company.  This Amendment constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms except as such enforceability may be limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and (ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).
(c)    No approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery or performance by, or enforcement against, the Company of this Amendment, except for those which have been made or obtained and are in full force and effect and except for any filing of this Amendment with the SEC.
(d)    The representations and warranties of (i) the Borrowers contained in Article 5 and (ii) each Loan Party contained in each other Loan Document or in any document furnished at any time under or in connection herewith or therewith, (x) that in either case (i) or (ii) are qualified by materiality shall be true and correct on and as of the Amendment Effective Date, and (y) that are not qualified by materiality, shall be true and correct in all material respects on and as of the Amendment Effective Date; except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct as of such earlier date.
(e)    After giving effect to this Amendment, no event has occurred and is continuing which constitutes a Default or an Event of Default.
(f)    Except as specifically provided in this Amendment, the Obligations are not reduced or modified by this Amendment and are not subject to any offsets, defenses or counterclaims.
3.4    Reaffirmation of Obligations, etc.  The Company hereby ratifies the Credit Agreement (including after giving effect to this Amendment) and acknowledges and reaffirms (a) that it is bound by all terms of the Credit Agreement (including after giving effect to this Amendment) applicable to it and (b) that it is responsible for the observance and full performance of its respective Obligations.  The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Administrative Agent under any of the Loan Documents, nor constitute a waiver of any provision of any of the Loan Documents.
3.5    Loan Document.  This Amendment shall constitute a Loan Document under the terms of the Credit Agreement.
3.6    Further Assurances.  The Company agrees to promptly take such action, upon the request of the Administrative Agent, as is necessary to carry out the intent of this Amendment.

6

3.7    Entirety.  This Amendment and the other Loan Documents embody the entire agreement among the parties hereto and supersede all prior agreements and understandings, oral or written, if any, relating to the subject matter hereof.
3.8    Counterparts; Telecopy.  This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be an original, but all of which shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page of this Amendment or any other document required to be delivered hereunder, by fax transmission or e-mail transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Agreement.  Without limiting the foregoing, upon the request of any party, such fax transmission or e-mail transmission shall be promptly followed by such manually executed counterpart.
3.9    No Actions, Claims, Etc.  As of the date hereof, the Company hereby acknowledges and confirms that it has no knowledge of any actions, causes of action, claims, demands, damages and liabilities of whatever kind or nature, in law or in equity, against the Administrative Agent, the Lenders, or the Administrative Agent’s or the Lenders’ respective officers, employees, representatives, agents, counsel or directors arising from any action by such Persons, or failure of such Persons to act under the Credit Agreement on or prior to the date hereof.  
3.10    GOVERNING LAW.  THIS AMENDMENT SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.
3.11    Successors and Assigns.  This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.
3.12    Consent to Jurisdiction; Service of Process; Waiver of Jury Trial; California Judicial Reference.  The jurisdiction, service of process, waiver of jury trial and California judicial reference provisions set forth in Sections 10.14, 10.15 and 10.16 of the Credit Agreement are hereby incorporated by reference, mutatis mutandis.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

7

IN WITNESS WHEREOF the parties hereto have caused this Amendment to be duly executed on the date first above written.
	
			
	COMPANY:
	 
	ADOBE SYSTEMS INCORPORATED,

	 
	 
	a Delaware corporation 

	 
	 
	 

	 
	 
	By: /s/ Mark S. Garrett     

	 
	 
	     Name: Mark. S. Garrett 

	 
	 
	     Title: Executive Vice President, Chief Financial Officer

	 
	 
	 

	 
	 
	 

	 
	 
	 

	ADMINISTRATIVE AGENT:
	 
	BANK OF AMERICA, N.A., in its capacity as Administrative

	 
	 
	Agent 

	 
	 
	 

	 
	 
	By: /s/ Robert Rittelmeyer     

	 
	 
	     Name: Robert Rittelmeyer 

	 
	 
	     Title: Vice President

	 
	 
	 

	 
	 
	 

	 
	 
	 

	LENDERS:
	 
	BANK OF AMERICA, N.A., in its capacity as a Lender,

	 
	 
	including as Swing Line Lender 

	 
	 
	 

	 
	 
	By: /s/ My-Linh Yoshiike    

	 
	 
	     Name: My-Linh Yoshiike 

	 
	 
	     Title: Vice President

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	JPMORGAN CHASE BANK, N.A.

	 
	 
	in its capacity as a Lender

	 
	 
	 

	 
	 
	By: /s/ Peter Thauer     

	 
	 
	     Name: Peter Thauer 

	 
	 
	     Title: Managing Director

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	U.S. BANK NATIONAL ASSOCIATION, in its capacity as a

	 
	 
	Lender 

	 
	 
	 

	 
	 
	By: /s/ Matt S. Scullin     

[Signature Page to First Amendment to Credit Agreement]
 

	
			
	 
	 
	      Name: Matt S. Scullin

	 
	 
	      Title: Vice President

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	WELLS FARGO BANK, NATIONAL ASSOCIATION, in its

	 
	 
	 capacity as a Lender 

	 
	 
	 

	 
	 
	By: /s/ Lacy Houstoun     

	 
	 
	     Name: Lacy Houstoun 

	 
	 
	     Title: Director

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	MIZUHO BANK, LTD., 

	 
	 
	in its capacity as a Lender 

	 
	 
	 

	 
	 
	By: /s/ Bertram H. Tang     

	 
	 
	     Name: Bertram H. Tang 

	 
	 
	     Title: Authorized Signatory

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	HSBC BANK USA, NATIONAL ASSOCIATION, 

	 
	 
	in its capacity as a Lender 

	 
	 
	 

	 
	 
	By: /s/ Stephanie W Lee     

	 
	 
	       Name: Stephanie W Lee 

	 
	 
	       Title: Vice President

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	The Bank of Tokyo-Mitsubishi UFJ, Ltd., in its capacity as a

	 
	 
	Lender

	 
	 
	 

	 
	 
	By: /s/ Lillian Kim     

	 
	 
	       Name: Lillian Kim 

	 
	 
	       Title: Director

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	THE NORTHERN TRUST COMPANY, 

	 
	 
	in its capacity as a Lender 

[Signature Page to First Amendment to Credit Agreement]

	
			
	 
	 
	 

	 
	 
	By: /s/ John Lascody     

	 
	 
	       Name: John Lascody 

	 
	 
	       Title: Vice President

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	MORGAN STANLEY SENIOR FUNDING, INC., 

	 
	 
	in its capacity as a Lender 

	 
	 
	 

	 
	 
	By: /s/ Michael King    

	 
	 
	       Name: Michael King 

	 
	 
	       Title: Vice President

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	MORGAN STANLEY BANK, N.A., 

	 
	 
	in its capacity as a Lender 

	 
	 
	 

	 
	 
	By: /s/ Michael King     

	 
	 
	       Name: Michael King 

	 
	 
	       Title: Authorized Signatory

[Signature Page to First Amendment to Credit Agreement]

EXHIBIT A TO FIRST AMENDMENT

SCHEDULE 2.01

	
			
	LENDER
	FACILITY ALLOCATION
	APPLICABLE PERCENTAGE

	Bank of America, N.A.
	$145,000,000.00
	14.500000000%

	JPMorgan Chase Bank, N.A.
	$145,000,000.00
	14.500000000%

	U.S. Bank National Association
	$145,000,000.00
	14.500000000%

	Wells Fargo Bank, National Association
	$145,000,000.00
	14.500000000%

	Mizuho Bank, Ltd.
	$101,250,000.00
	10.125000000%

	HSBC Bank USA, National Association
	$101,250,000.00
	10.125000000%

	The Bank of Tokyo-Mitsubishi UFJ, Ltd.
	$72,500,000.00
	7.250000000%

	The Northern Trust Company
	$72,500,000.00
	7.250000000%

	Morgan Stanley Senior Funding, Inc.
	$64,000,000.00
	6.400000000%

	Morgan Stanley Bank, N.A.
	$8,500,000.00
	0.850000000%

	TOTAL
	$1,000,000,000.00
	100.000000000%Exhibit 4.33

 

AMENDED AND RESTATED LOAN NOTE

 

	
$400,000,000
    	
June 18, 2015
    

 

FOR VALUE RECEIVED, Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares; Fresenius Medical Care Holdings, Inc., a New York corporation; National Medical Care, Inc., a Delaware corporation; Bio-Medical Applications of Alabama, Inc., a Delaware Corporation; Bio-Medical Applications of California, Inc., a Delaware corporation; Bio-Medical Applications of Delaware, Inc., a Delaware corporation; Bio-Medical Applications of Georgia, Inc., a Delaware corporation; Bio-Medical Applications of Kentucky, Inc., a Delaware corporation; Bio-Medical Applications of Louisiana, LLC, a Delaware limited liability company; Bio-Medical Applications of Minnesota, Inc., a Delaware corporation; Bio-Medical Applications of Mississippi, Inc., a Delaware corporation; Bio-Medical Applications of New Hampshire, Inc., a Delaware corporation; Bio-Medical Applications of New Jersey, Inc., a Delaware corporation; Bio-Medical Applications of New Mexico, Inc., a Delaware corporation; Bio-Medical Applications of North Carolina, Inc., a Delaware corporation; Bio-Medical Applications of Ohio, Inc., a Delaware corporation; Bio-Medical Applications of Pennsylvania, Inc., a Delaware corporation; Bio-Medical Applications of Tennessee, Inc., a Delaware corporation; Bio-Medical Applications of Texas, Inc., a Delaware corporation ; Bio-Medical Applications of West Virginia, Inc., a Delaware corporation; Bio-Medical Applications of Virginia, Inc., a Delaware corporation; Fresenius USA Manufacturing, Inc., a Delaware corporation; Fresenius USA Marketing, Inc., a Delaware corporation; Fresenius USA, Inc., a Massachusetts corporation; Spectra Laboratories, Inc., a Nevada corporation; WSKC Dialysis Services, Inc., an Illinois corporation; Fresenius Management Services, Inc., a Delaware corporation; Renal Care Group, Inc., a Delaware corporation; Dialysis Centers of America — Illinois, Inc., an Illinois corporation; Renal Care Group of the Midwest, Inc., a Kansas corporation; Renal Advantage Holdings, Inc., a Delaware corporation; Renal Advantage Inc., a Delaware corporation; Bio-Medical Applications of Wisconsin, Inc., a Delaware corporation; Fresenius Medical Care Ventures Holding Company, Inc., a Delaware corporation; Renal Care Group of the South, Inc., a Delaware corporation; Renal Care Group Alaska, Inc., an Alaska corporation; Renal Care Group East, Inc., a Pennsylvania corporation; RCG Mississippi, Inc., a Delaware corporation; Renal Care Group Northwest, Inc., a Delaware corporation; RCG University Division, Inc., a Tennessee corporation; Renex Dialysis Clinic of Woodbury, Inc., a New Jersey corporation; Spectra East, Inc., a Delaware corporation; Bio-Medical Applications of South Carolina, Inc., a Delaware corporation; Fresenius Medical Care Rx, LLC, a Delaware limited liability company; Fresenius Medical Care Pharmacy Services, Inc., a Delaware corporation; Bio-Medical Applications of Illinois, Inc., a Delaware corporation; FMS New York Services, LLC, a Delaware limited liability company; and NNA Management Company of Kentucky, Inc., a Kentucky corporation (collectively, the “Borrowers”), jointly and severally promise to pay to the order of Fresenius SE & Co. KGaA, a German partnership limited by shares, or its specified subsidiary (the “Lender”) the lesser of (i) the 

 

 

principal amount of $400,000,000 (Four Hundred Million Dollars) (or the US Dollar equivalent of any amount denominated in any other currency as determined by Lender based on the spot rate as reasonably selected by Lender), or (ii) the unpaid principal amount of all Advances (as defined in Section 2) made by the Lender to the Borrowers hereunder, together with interest accrued thereon at the rate set forth below, on the date specified for repayment of such Advance pursuant to Clause 3 hereof or such earlier date as such amounts may become payable pursuant to the terms hereof.

 

1.        The following terms used in this Note shall have the following meanings:

 

“FMC Credit Agreement” means the Credit Agreement dated as of October 30, 2012 among FMC and FMCH, as borrowers and guarantors, the other borrowers and guarantors party thereto, the lenders party thereto, Bank of America, N.A., as Administrative Agent, as amended, restated, supplemented, or otherwise modified, or renewed, refunded, replaced, or refinanced from time to time.

 

“FMC” means Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, and its successors and permitted assigns.

 

“FMCH” means Fresenius Medical Care Holdings, Inc., a New York corporation, and its successors and permitted assigns.

 

All other capitalized terms used but not otherwise defined herein shall bear the meanings assigned thereto in the FMC Credit Agreement.  This Note amends and restates and supersedes the Loan Note dated as of June 30, 2014 (the “Original Note”) in the original principal amount of $400,000,000 issued by the borrowers party thereto to Lender.  The Borrowers and Lender hereby agree that with effect from November 26, 2014, (i) all loans outstanding under the Original Note shall be deemed loans made under this Note and subject to the terms hereunder, (ii) the borrowers identified on Schedule I hereto shall be borrowers under this Note, and (iii) the borrowers identified on Schedule II hereto shall be released from all obligations under and in respect of the Original Note.

 

2.        The Lender may lend (but shall not have any commitment to lend) one or more advances (each an “Advance”) to the Borrowers jointly and severally from time to time upon request during the period from the date hereof to but excluding October 30, 2017 in an aggregate amount which shall not exceed $400,000,000 (or the US Dollar equivalent of any amount denominated in any other currency as determined by Lender based on the spot rate as reasonably selected by Lender).  Amounts borrowed hereunder may be repaid and reborrowed. The Lender shall have no obligation to make any Advance requested hereunder.

 

3.        Each Advance shall be repaid in full on the date that is one, two or three months after the date on which it is made, as agreed by the Borrowers and the Lender on the date such Advance is made, or any other period agreed between the Borrowers and the Lender; provided, that if no maturity date is so agreed, such Advance shall have a term of one month.

 

2

 

4.        Borrowers and Lender hereby agree that from and after November 26, 2014, the unpaid principal amount of each Advance made hereunder shall bear interest at a fluctuating rate per annum equal to the Fixed LIBOR Rate (as defined in and calculated pursuant to the FMC Credit Agreement) for an Interest Period equivalent to the term of such Advance plus a margin, determined pursuant to the pricing matrix set forth below, that is based on the Consolidated Leverage Ratio (as defined in and calculated pursuant to the FMC Credit Agreement), and shall change as and when the Applicable Percentage (as defined in and calculated pursuant to the FMC Credit Agreement) changes:

 

	
Pricing Level
    	
 
    	
Consolidated
   Leverage Ratio
    	
 
    	
Margin
    	
 
    
	
I
    	
 
    	
> 3.5:1.0
    	
 
    	
1.355
    	
%
    
	
II
    	
 
    	
> 3.0:1.0 but < 3.5:1.0
    	
 
    	
1.280
    	
%
    
	
III
    	
 
    	
> 2.5:1.0 but < 3.0:1.0
    	
 
    	
1.170
    	
%
    
	
IV
    	
 
    	
> 2.0:1.0 but < 2.5:1.0
    	
 
    	
1.100
    	
%
    
	
V
    	
 
    	
< 2.0:1.0
    	
 
    	
0.980
    	
%
    

 

Interest shall be payable in arrears upon maturity, on any prepayment and on any acceleration of the principal amount hereof and shall be computed on the basis of a 360-day year for the actual number of days elapsed (including the first day and excluding the last day).

 

5.        Whenever any payment on this Note shall be stated to be due on a day which is not a Business Day or is a day on which commercial banks are authorized or required by law to close in the Federal Republic of Germany, such payment shall be made on the next succeeding Business Day on which commercial banks are not authorized or required by law to close in the Federal Republic of Germany, and such extension of time shall be included in the computation of the payment of interest on this Note.

 

6.        All payments of principal and interest in respect of this Note shall be made in lawful money of the United States in same day funds to the Lender’s account as notified in writing by the Lender.

 

7.        If any proceeding under any Debtor Relief Law shall be commenced by or against the Borrowers, all amounts of principal and accrued interest outstanding under this Note shall become immediately due and payable.

 

8.         The Lender agrees, by its acceptance hereof, that before disposing of this Note or any part hereof it will make a notation hereon of all Advances, the maturity date of each such Advance and principal payments previously made hereunder and of the date to which interest hereon has been paid; provided, however, that the failure to make a notation of any Advance or any payment made on this Note shall not limit or otherwise affect the obligation 

 

3

 

of the Borrowers hereunder with respect to payments of principal or interest on this Note.

 

9.         Any Borrower may cease to be a Borrower hereunder by delivering a written notice to the Lender, effective on the later to occur of (i) the date the Lender receives such written notice and (ii) the date such Borrower has paid all of its obligations and all accrued and unpaid interest, fees and other obligations hereunder or in connection herewith.

 

10.       Upon the formation, acquisition (other receipt of interests) or existence of any Material Domestic Subsidiary of FMCH that is not a Borrower hereunder, such Material Domestic Subsidiary may become a Borrower hereunder by executing an amendment to this Note.

 

11.       THIS NOTE AND THE OBLIGATIONS OF THE BORROWERS ARISING HEREUNDER AND ALL OTHER ASPECTS HEREOF SHALL BE DEEMED TO BE MADE UNDER, SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF NEW YORK WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.

 

12.       The obligations of the Borrowers arising under this Note may be prepaid in whole or in part, together with all accrued interest thereon, without penalty or premium.

 

13.       The terms of this Note are subject to amendment only by a writing signed by the Borrowers and the Lender.

 

14.       In no event shall any interest be payable under this Note to the extent that the payment thereof would be prohibited by applicable law.

 

15.       The Borrowers hereby waives diligence, presentment, protest, demand and notice of every kind and, to the full extent permitted by law, the right to plead any statute of limitations as a defense to any demand hereunder.

 

16.       No delay on the part of the Lender in the exercise of any right or remedy shall operate as a waiver thereof, and no single or partial exercise by the Lender, of any right or remedy shall preclude any other or further exercise of any other right or remedy.

 

17.       In case any provision in or obligation under this Note shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

 

[Remainder of page intentionally left blank]

 

4

 

IN WITNESS WHEREOF, this Note has been executed as of the day and year first written above.

 

 

	
BORROWERS:
    	
 
    
	
 
    	
 
    
	
 
    	
FRESENIUS MEDICAL   CARE AG & Co. KGaA, a German   partnership limited by shares, represented by FRESENIUS MEDICAL CARE MANAGEMENT AG, a German corporation, its general partner
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
s/ Michael Brosnan
    
	
 
    	
Name: Michael Brosnan
    
	
 
    	
Title: Member of the Management Board
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
s/ Dominik Wehner
    
	
 
    	
Name: Dominik Wehner
    
	
 
    	
Title: Member of the Management Board
    

 

[Signature Page —Loan Note]

 

 

FRESENIUS MEDICAL CARE HOLDINGS, INC., a New York corporation

NATIONAL MEDICAL CARE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF ALABAMA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF CALIFORNIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF DELAWARE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF GEORGIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF KENTUCKY, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF LOUISIANA, LLC, a Delaware limited liability company

BIO-MEDICAL APPLICATIONS OF MINNESOTA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF MISSISSIPPI, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW HAMPSHIRE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW JERSEY, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW MEXICO, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NORTH CAROLINA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF OHIO, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF PENNSYLVANIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF TENNESSEE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF TEXAS, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF WEST VIRGINIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF VIRGINIA, INC., a Delaware corporation

FRESENIUS USA MANUFACTURING, INC., a Delaware corporation

FRESENIUS USA MARKETING, INC., a Delaware corporation

FRESENIUS USA, INC., a Massachusetts corporation

SPECTRA LABORATORIES, INC., a Nevada corporation

WSKC DIALYSIS SERVICES, INC., an Illinois corporation

FRESENIUS MANAGEMENT SERVICES, INC., a Delaware corporation

RENAL CARE GROUP, INC., a Delaware corporation

DIALYSIS CENTERS OF AMERICA — ILLINOIS, INC., an Illinois corporation

RENAL CARE GROUP OF THE MIDWEST, INC., a Kansas corporation

RENAL ADVANTAGE HOLDINGS, INC., a Delaware corporation

RENAL ADVANTAGE INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF WISCONSIN, INC., a Delaware corporation

FRESENIUS MEDICAL CARE VENTURES HOLDING COMPANY, INC., a Delaware corporation

RENAL CARE GROUP OF THE SOUTH, INC., a Delaware corporation

RENAL CARE GROUP ALASKA, INC., an Alaska corporation

RENAL CARE GROUP EAST, INC., a Pennsylvania corporation

RCG MISSISSIPPI, INC., a Delaware corporation

RENAL CARE GROUP NORTHWEST, INC., a Delaware corporation

RCG UNIVERSITY DIVISION, INC., a Tennessee corporation

RENEX DIALYSIS CLINIC OF WOODBURY, INC., a New Jersey corporation

SPECTRA EAST, INC., a Delaware corporation

FRESENIUS MEDICAL CARE RX, LLC, a Delaware limited liability company

FRESENIUS MEDICAL CARE PHARMACY SERVICES, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF SOUTH CAROLINA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF ILLINOIS, INC., a Delaware corporation

FMS NEW YORK SERVICES, LLC, a Delaware limited liability company

NNA MANAGEMENT COMPANY OF KENTUCKY, INC., a Kentucky corporation

 

 

	
By:
    	
s/ Mark Fawcett
    	
 
    
	
Name: Mark Fawcett
    	
 
    
	
Title:   Vice President and Treasurer for each of   the foregoing
    	
 
    

 

[Signature Page —Loan Note]

 

 

	
ACKNOWLEDGED AND AGREED:
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
FRESENIUS SE & Co. KGaA, represented by FRESENIUS MANAGEMENT SE, its general partner, as   Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
s/ Stephan Sturm
    
	
 
    	
Name: Stephan Sturm
    
	
 
    	
Title: CFO
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
s/ Dr. Karl-Dieter   Schwab
    
	
 
    	
Name: ppa. Dr. Karl-Dieter Schwab
    
	
 
    	
Title: SVP Finance and Prokurist
    

 

[Signature Page —Loan Note]

 

 

TRANSACTIONS ON PROMISSORY NOTE

 

	
Date
    	
 
    	
Amount of
   Advance Made
   This Date
    	
 
    	
Maturity Date
   of Such
   Advance
    	
 
    	
Amount of
   Principal Paid
   This Date
    	
 
    	
Amount of
   Interest Paid
   This Date
    	
 
    	
Outstanding
   Principal
   Balance This
   Date
    	
 
    	
Notation Made
   By
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

 

Schedule I

 

Additional Borrowers

 

FRESENIUS MEDICAL CARE RX, LLC, a Delaware limited liability company

FRESENIUS MEDICAL CARE PHARMACY SERVICES, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF ILLINOIS, INC., a Delaware corporation

FMS NEW YORK SERVICES, LLC, a Delaware limited liability company

NNA MANAGEMENT COMPANY OF KENTUCKY, INC., a Kentucky corporation

 

 

Schedule II

 

Released Borrowers

 

BIO-MEDICAL APPLICATIONS OF INDIANA, INC., a Delaware corporation

QUALICENTERS EUGENE-SPRINGFIELD, LTD., a Colorado limited liability company

QUALICENTERS INLAND NORTHWEST, LLC, a Colorado limited liability company

QUALICENTERS PUEBLO, LLC, a Colorado limited liability company

QUALICENTERS SIOUX CITY, LLC, a Colorado limited liability company

BIO-MEDICAL APPLICATIONS OF FLORIDA, INC., a Delaware corporation

NNA OF NEVADA, INC., a Nevada corporation

Bio-Medical Applications OF MARYLAND, Inc., a Delaware corporation

LIBERTY DIALYSIS, LLC, a Delaware limited liability company

AMERICAN ACCESS CARE HOLDINGS, LLC, a Delaware limited liability company

BIO-MEDICAL APPLICATIONS OF MISSOURI, INC., a Delaware corporation

DIALYSIS MANAGEMENT CORPORATION, a Texas corporation

NNA OF ALABAMA, INC., an Alabama corporation

BIO-MEDICAL APPLICATIONS OF FAYETTEVILLE, INC., a Delaware corporation

RENAL CARE GROUP OF THE SOUTHEAST, INC., a Florida corporation

RENAL CARE GROUP TEXAS, INC., a Texas corporation

RENAL CARE GROUP SOUTHWEST HOLDINGS, INC., a Delaware corporation

RENAL RESEARCH INSTITUTE, LLC, a New York limited liability company

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]